Objectif Malaria is a global health priority that has been targeted for elimination in recent years. Attaining the goals that define elimination of malaria in different countries depends critically on provision of effective antimalarials and further that these antimalarials are used appropriately in individual patients. Drug resistance is a major threat to malaria control and has important global public health implications. Over the past decades the genetic bases for resistance to most of the antimalarial classes currently in use has become defined. For some drugs and combinations, these mutations are the most important predictors of treatment failure. This proposal will innovate new technologies to confirm malaria diagnosis and detect drug resistance in malaria parasites by analysis of mutations in nucleic acids, using nanowire technology, and will result in the development of a simple, rapid and affordable point-of-care handheld diagnostic device. The device will be useful at many levels in malarial control by:1. Optimising individual treatments for patients2. Assessing the epidemiology of drug resistance in malaria endemic areas3. Assessing population impacts of antimalarial interventionsThe development programme capitalises on highly original and proprietary advances made by QuantuMDx in the field of point-of-care diagnostics. This is complemented by academic expertise that has made major contributions to the understanding of antimalarial drug resistance mechanisms in laboratory models, as well as parasites obtained directly from patients. The impact of this proposal can be extended rapidly to other established and emerging infectious diseases. Champ scientifique medical and health scienceshealth sciencesinfectious diseasesmalarianatural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acidsmedical and health scienceshealth sciencespublic healthepidemiologymedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancenatural sciencesbiological sciencesgeneticsmutation Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2012.2.3.0-1 - Diagnostics for infectious diseases in humans Appel à propositions FP7-HEALTH-2012-INNOVATION-2 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur ST GEORGE'S HOSPITAL MEDICAL SCHOOL Contribution de l’UE € 994 655,00 Adresse CRANMER TERRACE SW17 0RE London Royaume-Uni Voir sur la carte Région London Inner London — West Wandsworth Type d’activité Higher or Secondary Education Establishments Contact administratif Jane Boland (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (3) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire QUANTUMDX GROUP LIMITED Royaume-Uni Contribution de l’UE € 2 629 416,00 Adresse LUGANO BUILDING 57 MELBOURNE STREET CR8 4EJ NEWCASTLE UPON TYNE Voir sur la carte Région London Outer London — South Croydon Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Elaine Warburton (Mrs.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée EBERHARD KARLS UNIVERSITAET TUEBINGEN Allemagne Contribution de l’UE € 172 200,00 Adresse GESCHWISTER-SCHOLL-PLATZ 72074 Tuebingen Voir sur la carte Région Baden-Württemberg Tübingen Tübingen, Landkreis Type d’activité Higher or Secondary Education Establishments Contact administratif Carsten Köhler (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée KAROLINSKA INSTITUTET Suède Contribution de l’UE € 195 879,00 Adresse Nobels Vag 5 17177 Stockholm Voir sur la carte Région Östra Sverige Stockholm Stockholms län Type d’activité Higher or Secondary Education Establishments Contact administratif Miles Davies (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
